Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody-drug conjugate in breast cancer.

Oncol Rev · 2026 · PMC12916699 · PMID 41726150

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

Accordingly, novel ADCs are being actively investigated in breast cancer; the most commonly diagnosed malignancy in women ( 11 ), with an observed trend toward a decreasing age at diagnosis ( 12 ).

also in 258 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.